SEARCH

SEARCH BY CITATION

References

  • Aperis G, Myrionis N, Spanakis EK & Mylonakis E (2006) Developments in the treatment of candidiasis: more choices and new challenges. Expert Opin Invest Drugs 15: 13191336.
  • Barrett SV & Barrett MP (2000) Anti-sleeping sickness drugs and cancer chemotherapy. Parasitol Today 16: 79.
  • Cadene M, Duranton J, North A, Si-tahar M, Chignard M & Bieth JG (1997) Inhibition of neutrophil serine proteinases by suramin. J Biol Chem 272: 99509955.
  • Casanova M, Cervera AM, Gozalbo D & Martinez JP (1997) Hemin induces germ tube formation in Candida albicans. Infect Immun 65: 43604364.
  • Castilla R, Passeron S & Cantore ML (1998) N-acetyl-d-glucosamine induces germination in Candida albicans through a mechanism sensitive to inhibitors of cAMP-dependent protein kinase. Cell Signal 10: 713719.
  • Cirillo A, Chifflet S & Villar B Neural retina of chick embryo in organ culture: effects of blockade of growth factors by suramin. Cell Tissue Res 304: 323331.
  • Constantopoulos G, Rees S, Cragg BG, Barranger JA & Brady RO (1983) Suramin-induced storage disease. Mucopolysaccharidosis. Am J Pathol 113: 266268.
  • Costa EMMB, Santos ALS, Cardoso AS, Portela MB, Abreu CM, Alviano CS, Hagler NA & Soares RMA (2003) Heterogeneity of metallo and serine proteinase in oral clinical isolates of Candida albicans in HIV-positive and healthy children from Rio de Janeiro, Brazil. FEMS Immunol Med Microbiol 38: 173180.
  • De Clerq E (1979) Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett 8: 922.
  • Eggimann P, Garbino J & Pittet D (2003) Management of Candida species infections in critically ill patients. Lancet Infect Dis 3: 772785.
  • Gschwendt M, Kittstein W & Johannes FJ (1998) Differential effects of suramin on protein kinase C isoenzymes. A novel tool for discriminating protein kinase C activities. FEBS Lett 421: 165168.
  • Hauman CH, Thompson IO, Theunissen F & Wolfaardt P (1993) Oral carriage of Candida in healthy and HIV-seropositive persons. Oral Surg Oral Med Oral Pathol 76: 570572.
  • Hazen KC & Cutler JE (1979) Autoregulation of germ tube formation by Candida albicans. Infect Immun 24: 661666.
  • He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA & Kauffman CA (1994) Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 38: 24952497.
  • Hilgers LA, Snippe H, Jansze M & Willers JM (1985) Effect of in vivo administration of different adjuvants on the in vitro candidacidal activity of mouse peritoneal cells. Cell Immunol 90: 1423.
  • Kehinde EO, Terry TR, Mistry N, Horsburgh T, Sandhu DP & Bell PR (1995) UK studies on suramin therapy in hormone resistant prostate cancer. Cancer Surv 23: 217229.
  • Kosarek CE, Hu X, Couto CG, Kisseberth WC, Green EM & Au JL (2006) Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. J Vet Intern Med 20: 11721177.
  • Kumamoto CA & Vinces MD (2005) Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell Microbiol 7: 15461554.
  • Meyer-Fernandes JR (2002) Ecto-ATPases in protozoa parasites: looking for a function. Parasitol Int 51: 299303.
  • Naglik JR, Challacombe SJ & Hube B (2003) Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67: 400428.
  • Ohmori T, Yatomi Y, Okamoto H, Miura Y, Rile G, Satoh K & Ozaki Y (2001) G(i)-mediated Cas tyrosine phosphorylation in vascular endothelial cells stimulated with sphingosine 1-phosphate: possible involvement in cell motility enhancement in cooperation with Rho-mediated pathways. J Biol Chem 76: 52745280.
  • Olaechea PM, Palomar M, Leon-Gil C, Alvarez-Lerma F, Jorda R, Nolla-Salas J & Leon-Regidor MA (2004) Epcan study Group. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 23: 323330.
  • Ostrosky-Zeichner L & Pappas PG (2006) Invasive candidiasis in the intensive care unit. Crit Care Med 34: 857863.
  • Pfaller MA, Lockhart SR, Pujol C, Swails-Wenger JA, Messer SA, Edmond MB, Jones RN, Wenzel RP & Soll DR (1998) Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. Clin Microb 36: 15181529.
  • Portela MB, Souza IPR, Costa EMMB, Hagler AN, Soares RMA & Santos ALS (2004) Differential recovery of Candida species from subgingival sites in human immunodeficiency virus-positive and healthy children from Rio de Janeiro, Brazil. J Clin Microbiol 41: 59255927.
  • Regmi A, Fuson T, Yang X, Kays J, Moxham C, Zartler E, Chandrashekhar S & Galvin RJ (2005) Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. Bone 36: 284291.
  • Rentz AM, Halpern MT & Bowden R (1998) The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 27: 781788.
  • Ruiz-Herrera J, Elorza MV, Valentim E & Sentandreu R (2006) Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity. FEMS Yeast Res 6: 1429.
  • Stein CA, LaRocca RV, Thomas R, McAtee N & Myers CE (1989) Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499508.
  • Trinquier M, Perie J, Callens M, Opperdoes F & Willson M (1995) Specific inhibitors for the glycolytic enzymes of Trypanosoma brucei. Bioorg Med Chem 3: 14231427.
  • Voogd TE, Vansterkenburg EL, Wilting J & Janssen LH (1993) Recent research on the biological activity of suramin. Pharmacol Rev 45: 177203.
  • Zhang YL, Keng YF, Zhao Y, Wu L & Zhang ZY (1998) Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J Biol Chem 273: 1228112287.